Literature DB >> 12010892

Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model.

D W Y Ho1, S T Fan, J To, Y H Woo, Z Zhang, C Lau, J Wong.   

Abstract

BACKGROUND: Plasma exchange may be useful for treating patients with fulminant hepatic failure but during the procedure growth factors that are important for hepatic regeneration are discarded. Addition of a selective plasma filter to the plasmapheresis circuit could eliminate protein bound toxic substances and retain growth factors for hepatic regeneration. This process is called selective plasma filtration. AIMS: To determine if selective plasma filtration could be a useful treatment modality for fulminant hepatic failure.
METHODS: The system was tested in five groups of pigs with fulminant hepatic failure induced by galactosamine: group I, diseased control group (n=5); group II, sham control, (n=6); group III, plasma exchange (n=6); group IV, treatment with AC-1770 selective plasma filter (n=7); and group V, treatment with AC-1730 selective plasma filter which had a smaller pore size than AC-1770 (n=7). Fresh pig plasma was given to replace filtered plasma in pigs of groups III, IV, and V. Treatment was initiated 48 hours after administration of 0.75 g/kg galactosamine. The efficacy of selective plasma filtration was assessed by survival rate and improvement in haematological, biochemical, and immunohistological parameters.
RESULTS: Pigs treated with AC-1770 or AC-1730 selective plasma filters survived longer than the other groups (group I: 55 (10) hours; group II: 68 (7) hours; group III: 91 (10) hours; group IV: 269 (156) hours; group V: 950 (555) hours). One pig in group IV survived for 50 days; one pig in group V survived for 77 days and another pig in group V is still alive (>150 days). After treatment, plasma levels of aspartate aminotransferase, bilirubin, bile acid, ammonia, lactate dehydrogenase, and alpha-glutathione-S-transferase decreased. Substantial amounts of tumour necrosis factor alpha (TNF-alpha) and endotoxin were found in the filtrate. The selective plasma filtration groups retained significantly higher amounts of hepatocyte growth factor than plasma exchange alone. Similar TNF-alpha clearance was observed in the selective plasma filtration groups and the plasma exchange group. On day 4, significant improvement in liver function, as measured by the indocyanine green clearance test, was observed in groups IV and V but not in the other groups. A higher regeneration index of hepatocytes was also observed in the groups treated with AC-1770 and AC-1730 selective plasma filters.
CONCLUSION: Selective plasma filtration improved survival time and expedited liver regeneration in pigs with fulminant hepatic failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010892      PMCID: PMC1773226          DOI: 10.1136/gut.50.6.869

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Hepatocyte growth factor and vascular endothelial growth factor expression in pig-to-primate xenotransplanted hearts.

Authors:  K Takayama; J Suzuki; M Kawauchi; K Tsukioka; Y Wada; T Zhang; M Endoh; S Takamoto; J Amano; M Isobe
Journal:  Transplant Proc       Date:  2000-08       Impact factor: 1.066

Review 2.  Portal systemic encephalopathy.

Authors:  S Schenker; M K Bay
Journal:  Clin Liver Dis       Date:  1997-05       Impact factor: 6.126

3.  Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice.

Authors:  L J van der Laan; C Lockey; B C Griffeth; F S Frasier; C A Wilson; D E Onions; B J Hering; Z Long; E Otto; B E Torbett; D R Salomon
Journal:  Nature       Date:  2000-09-07       Impact factor: 49.962

4.  Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients.

Authors:  D J Ritt; G Whelan; D J Werner; E H Eigenbrodt; S Schenker; B Combes
Journal:  Medicine (Baltimore)       Date:  1969-03       Impact factor: 1.889

5.  Nonbiological liver support: historic overview.

Authors:  P S Malchesky
Journal:  Artif Organs       Date:  1994-05       Impact factor: 3.094

Review 6.  Emerging multipotent aspects of hepatocyte growth factor.

Authors:  K Matsumoto; T Nakamura
Journal:  J Biochem       Date:  1996-04       Impact factor: 3.387

7.  Preclinical trial of a bioartificial liver support system in a porcine fulminant hepatic failure model.

Authors:  A G Sheil; J Sun; D C Mears; M Waring; K Woodman; B Johnston; M Horvat; K J Watson; N Koutalistras; L S Wang
Journal:  Aust N Z J Surg       Date:  1996-08

Review 8.  Mechanisms of liver cell injury.

Authors:  N Kaplowitz
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

9.  A single institution's experience (1982-1999) with plasma-exchange therapy in patients with fulminant hepatic failure.

Authors:  G De Silvestro; P Marson; R Brandolese; G Pittoni; G Ongaro
Journal:  Int J Artif Organs       Date:  2000-07       Impact factor: 1.595

10.  Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience.

Authors:  H Bismuth; D Samuel; D Castaing; R Adam; F Saliba; M Johann; D Azoulay; B Ducot; L Chiche
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

View more
  13 in total

1.  Effects of hemoperfusion adsorption and/or plasma exchange in treatment of severe viral hepatitis: a comparative study.

Authors:  Nian-Hai He; Ying-Jie Wang; Ze-Wen Wang; Jun Liu; Jia-Jia Li; Guo-Dong Liu; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  Differential liver protein expression during schistosomiasis.

Authors:  Marina Harvie; Thomas William Jordan; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

3.  Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance.

Authors:  Ying Jiang; Miaoyun Zhao; Wei An
Journal:  J Mol Med (Berl)       Date:  2011-08-04       Impact factor: 4.599

4.  Pivotal preclinical trial of the spheroid reservoir bioartificial liver.

Authors:  Jaime M Glorioso; Shennen A Mao; Brian Rodysill; Taufic Mounajjed; Walter K Kremers; Faysal Elgilani; Raymond D Hickey; Hakon Haugaa; Christopher F Rose; Bruce Amiot; Scott L Nyberg
Journal:  J Hepatol       Date:  2015-03-25       Impact factor: 25.083

5.  Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.

Authors:  Yuan-Yuan Guo; Yuan Wu; Xiao-Wei Jia; Wei An
Journal:  Lab Invest       Date:  2017-08-21       Impact factor: 5.662

6.  Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B.

Authors:  Hui-Guo Ding; Jing Shan; Bin Zhang; Hong-Bo Ma; Li Zhou; Rui Jin; Yu-Fen Tan; Li-Xiang He
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

7.  Prophylactic uses of integrin CD18-betaA peptide in a murine polymicrobial peritonitis model.

Authors:  Kwong-Fai Wong; Jana Wo; David Ho; Ronnie T Poon; José M Casasnovas; John M Luk
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

8.  Adenoviral gene transfer of hepatic stimulator substance confers resistance against hepatic ischemia-reperfusion injury by improving mitochondrial function.

Authors:  Shu-Jun Jiang; Wen Li; Wei An
Journal:  Hum Gene Ther       Date:  2013-04       Impact factor: 5.695

9.  Assessment of resin perfusion in hepatic failure in vitro and in vivo.

Authors:  Ying-Jie Wang; Ze-Wen Wang; Bing-Wei Luo; Hong-Ling Liu; Hong-Wei Wen
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

10.  Inhibition of Drp1 SUMOylation by ALR protects the liver from ischemia-reperfusion injury.

Authors:  Jing Huang; Ping Xie; Yuan Dong; Wei An
Journal:  Cell Death Differ       Date:  2020-10-27       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.